ACE inhibitors hypothesis generation for selective design, synthesis and biological evaluation of 3-mercapto-2-methyl-propanoyl-pyrrolidine-3-imine derivatives as antihypertensive agents

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 10, 2009, Pages 3739-3746

  Ismail, Mohamed A H ^a   Nabil Aboul Enein, M ^b   Abouzid, Khaled A M ^a   Abou El Ella, Dalal A ^a   Ismail, Nasser S M ^a  

^a Ain Shams University   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

3 Mercapto 2 methyl propanoylpyrrolidines; ACE inhibitors hypothesis generation; Hypotensive agents; Molecular modeling

Indexed keywords

1 (3 MERCAPTO 2 METHYLPROPANOYL) 2 (4 METHOXYBENZYL)PYRROLIDIN 3 ONE; 1 [3 (2 HYDROXYETHYLIMINO) 2 (4 METHOXYBENZYL)PYRROLIDIN 1 YL] 3 MERCAPTO 2 METHYLPROPAN 1 ONE; 1 [3 (HYDROXYIMINO) 2 (4 METHOXYBENZYL)PYRROLIDIN 1 YL] 3 MERCAPTO 2 METHYLPROPAN 1 ONE; 3 MERCAPTO 2 METHYLPROPANOYLPYRROLIDIN 3 IMINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHYL 2 [1 (3 MERCAPTO 2 METHYLPROPANOYL) 2 (4 METHOXYBENZYL)PYRROLIDIN 3 YLIDENEAMINO]PROPANOATE; LISINOPRIL; RO 67 7447; RO 68 7629; UNCLASSIFIED DRUG; ZOFENOPRIL; ZOFENOPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYPERTENSION; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CATALYSIS; CATS; COMPUTER SIMULATION; DATABASES, PROTEIN; DRUG DESIGN; MODELS, CHEMICAL; MODELS, MOLECULAR; PROPIONIC ACIDS; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65449142952     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.03.008     Document Type: Article

References (24)

1. Jackson E.K., and Garrison J.C. Renin and Angiotensin. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., and Gilman A.G. (Eds). Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 9th ed. (1996), McGraw-Hill, New York 733-758
2. Brunner H.R., Nussberger J., and Wäber B. Angiotensin Antagonists. In: Robertson J.I.S., and Nicholls M.G. (Eds). The Renin-Angiotensin System (1993), Gower Medical Publishing, London 86.1-86.14
3. Smith R.D., and Timmermans P.B.M.W.M. Pharmacol. Res. 31 (1995) 289
4. Goodfriend T.L., Elliott M.E., and Catt K. N. Eng. J. Med. 334 (1996) 1649
5. Veelken R., Hilgers K.F., Scrogin K.E., Mann J.F.E., and Schmieder R.E. Br. J. Pharmacol. 125 (1998) 1761
6. Bottari S.P., de Gasparo M., Steckelings U.M., and Levens N.R. Front. Neuroendocrin. 14 (1993) 123
7. Raasch W., Bartels T., Gieselberg A., Dendorfer A., and Dominiak P. J. Pharmacol. Exp. Ther. 300 (2002) 428
8. Palkowitz A.D., Steinberg M.I., Thrasher K.J., Reel J.K., Hauser K.L., Zimmerman K.M., Wiest S.A., Whitesitt C.A., Simon R.L., Heifer W., Lifer S.L., Boyd D.B., Barnett C.J., Wilson T.M., Deeter J.B., Takeuchi K., Riley R.E., Miller W.D., and Marshall W.S. J. Med. Chem. 32 (1994) 4508
9. Guidelines Committee. J. Hypertens. 21 (2003) 1011
10. Kirch W., Horn B., and Schweizer J. Eur. J. Clin. Invest. 31 (2001) 698
11. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., Fyhrquist F., Ibsen H., Kristainsson K., Lederbalte-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., and Wedel H. Lancet 359 (2002) 995
12. Gordon E.M., Godfrey J.D., Weller H.N., Natarajan S., Pluscec J., Rom M.B., Niemela K., Sabo E.F., and Cushman D.W. Bioorganic Chem 14 (1986) 148
13. Wei W., ShengRong S., FengQin F., GuoQing H., and ZhanLi W. Sci. China, Ser. B-Chem. 51 (2008) 786
14. Zaluski M.C., Coric P., Thery V., Gonzallez W., Turcaud S., Michel J., and Roques B. J. Med. Chem. 39 (1996) 2594
15. Subissi A., Evangelista S., and Giachetti A. Cardiovasc. Drug Rev. 17 (1999) 115
16. Tzakos A.G., and Gerothanassis I.P. ChemBioChem 6 (2005) 1089
17. Crystal structure of Human ACE in complex with lisinoprol (1086),. Natesh R., Shwager S.L.U., Sturrock E.D., and Achorya K.R. Nature 421 (2003) 551
18. Dammkoehler R.A., Karasek S.K., Shands E.F.B., and Marshall G.R. J. Comput. Aided Mol. Des. 3 (1989) 3
19. Kustera D.J., and Marshalla G.R. J. Comput. Aided Mol. Des. 19 (2005) 609
20. Ismail N.S.M., Salah El Dine R., Hattori M., Takahashi K., and Ihara M. Bioorg. Med. Chem. 16 (2008) 7877
21. Ismail M.A.H., Todd M.H., Barker S., Abou El Ella D.A., Abouzid K.A.M., and Toubar R.A. J. Med. Chem. 49 (2006) 1526
22. Nabil Aboul-Enein M., Khalifa M., and El-Difrawy S.M. Pharm. Acta Helv. 48 (1973) 405
23. Mc Kinney L.L., Uhing W.H., Stezdorm E.A., and Cown J.C. J. Am. Chem. Soc. 72 (1950) 2599
24. Johnson A.L. J. Org. Chem. 41 (1976) 1320